Odit Gutwein

Odit Gutwein

Auto-generated profile, based on publicly available information

Odit Gutwein

Department of Hematology Shamir Medical Center (Assaf Harofeh) Zerifin Israel

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2026 in Blood Advances
Verified
Journal Article
Open access
TCThomas Chatzikonstantinou
Thomas Chatzikonstantinou
MMMariia Mikhaleva
Mariia Mikhaleva
CBChristian Brieghel
Christian Brieghel
CPChristina Papangelou
Christina Papangelou
EMEva Minga
Eva Minga
MKMaya Koren-Michowitz
Maya Koren-Michowitz
Central nervous system involvement (CNSi) of chronic lymphocytic leukemia (CLL) is a rare condition with no consensus on diagnostic criteria and limited evidence for management and outcome. Here, we report an international, multicenter, retrospective study conducted by the European Research Initiative on CLL. The study defined CNSi of CLL by the following: (1) detection of CLL cells in the cerebrospinal fluid or confirmation of CLL infiltration of the CNS based on a tissue biopsy, (2) clinical or radiographic evidence of neurologic disease, and (3) the absence of other explanations for the neurologic findings. A total of 48 patients from 26 centers in 15 countries met all 3 diagnostic criteria of CLL-CNSi. Median age at diagnosis of CNSi was 64 years. Most patients were males (73%), had Binet stage A at CLL diagnosis (61%), and had untreated CLL at the time of CNSi (63%). Motor impairment was the most common symptom (38%) followed by visual impairment (32%). Of 47 patients who received treatment for CNSi, half (51%) received targeted agents, most often a Bruton tyrosine kinase inhibitor (BTKi), and 34% received chemoimmunotherapy. Initial treatment was highly effective, leading to a reduction (83%) or complete resolution (71%) of neurologic symptoms and imaging findings in most patients. The estimated 5-year overall survival (OS) from the CNSi diagnosis was 77.1%. The 5-year time to next treatment or death was 94% for patients treated with BTKi compared with 64% for those treated with CIT. Treatment-sensitive disease, represented by attainment of CNS complete response after initial therapy, was associated with longer OS.

25 October 2023 in Cancer Medicine
Verified
Journal Article
Open access
OGOdit Gutwein
Odit Gutwein
KTKatrin Herzog Tzarfati
Katrin Herzog Tzarfati
AAArie Apel
Arie Apel
NRNaomi Rahimi-Levene
Naomi Rahimi-Levene
LILevy Ilana
Levy Ilana
MKMaya Koren‐Michowitz
Maya Koren‐Michowitz
The COVID-19 pandemic continues to pose challenges to the treatment of hemato-oncology patients. Emergence of COVID-19 variants, availability of vaccine boosters and antiviral treatments could impact their outcome. We retrospectively studied patients with hematologic malignancies and confirmed COVID-19 during the Omicron outbreak. Of 116 evaluated patients, 16% developed severe or critical COVID-19. Diagnosis of chronic lymphocytic leukemia (CLL) was significantly associated with severe COVID-19 (p = 0.01). The vaccine effectiveness was related to the timing of the vaccine, with patients who received a mRNA vaccine within 7-90 days prior to COVID-19 being less likely to develop severe disease compared to all other patients (p = 0.019). There was no correlation between disease severity and antiviral therapies. Importantly, 45% of patients undergoing active hematological treatment had to interrupt their treatment due to COVID-19. In conclusion, patients with hematologic malignancies are at a considerable risk for severe COVID-19 during the Omicron outbreak, with patients with CLL being the most vulnerable. mRNA vaccines have the potential to protect hematological patients from severe COVID-19 if administered within the previous 3 months. Hematological treatment interruption is a frequent adverse outcome of COVID-19 infection.

12 July 2022 in Journal of Medical Screening
Verified
Journal Article
Closed access
ELEfrat Luttwak
Efrat Luttwak
YSYafit Segman
Yafit Segman
MSMay Saban
May Saban
OGOdit Gutwein
Odit Gutwein
IAIrit Avivi
Irit Avivi
NSNadav Sarid
Nadav Sarid
Objective: To determine the rate of lymphoproliferative disease (LPD) in women undergoing routine breast cancer screening (BCS). BCS can reveal pathologies other than carcinoma that involve the breast and lymph tissue. The few studies that have described cases in which BCS led to the diagnosis of LPD were based on small series and focused on imaging rather than clinical characteristics. Setting and Methods: A multi-center retrospective study in Israel, investigating LPD rate and characteristics among women diagnosed with LPD via BCS. Results: Thirty-four patients out of 14,400 consecutive women undergoing BCS at Tel Aviv Sourasky Medical Center during the study period were diagnosed with LPD, suggesting a diagnosis rate of 0.24%. The enlarged cohort (n = 45), including 11 patients that were retrieved from the databases of three other centers, demonstrates a predominant histological diagnosis of non-aggressive LPD (n = 33). Thirty-four (76%) had a suspicious axillary lymph node, and 11 had a breast lesion. The median maximal lesion size was 1.95 cm (range 0.8–6.5). Disease was localized in 60% of patients (stage 1 and 1E). Univariate analysis revealed that lymphocyte count was inversely associated with aggressive histology. At median follow-up of 39 months, all but three patients were alive. These three had been diagnosed with non-aggressive LPD which had never been treated and died from unrelated causes. Conclusions: The LPD detection rate via BCS was 2.36 per 1000 screens. The majority of LPDs were non-aggressive. Nearly a third were aggressive, most detected at an early stage, and the clinical outcome was generally favorable.

30 June 2026
Verified
Conference Paper
Open access
YZYu Zhou
Yu Zhou
VVVladimir Vutov
Vladimir Vutov
SGSusmita Ghosh
Susmita Ghosh
FMFabienne Meier-Abt
Fabienne Meier-Abt
SPSibylle Pfammatter
Sibylle Pfammatter
JCJianxu Chen
Jianxu Chen

25 June 2022 in medRxiv
Verified
Preprint
Open access
PDF file
GSGuy Shapira
Guy Shapira
CWChen Weiner
Chen Weiner
RSReut Sorek-Abramovich
Reut Sorek-Abramovich
OGOdit Gutwein
Odit Gutwein
NRNir Rainy
Nir Rainy
NSNoam Shomron
Noam Shomron
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in immunocompromised patients may lead to accelerated viral mutation rate, immune evasion and persistent viral shedding over many months. Here we report the case of a severely immunocompromised cancer patient infected with the Delta variant of SARS-CoV-2 for over 8 months. Genome sequencing of samples taken after repeated monoclonal antibody treatments reveal the emergence and accumulation of mutations enabling escape from neutralization by antibodies. Mutations emerging in accessory and non-structural viral proteins target specific residues of immunomodulatory domains, potentially leading to loss of some functions, while preserving others. The mutated virus managed to completely overcome neutralization by monoclonal antibodies while remaining viable and infective. Our results suggest that the loss of specific immunomodulatory viral functions might confer a selective advantage in immunocompromised hosts. We also compare between mutations emerging in the presence and absence of neutralizing antibodies. Highlights: SARS-CoV-2 undergoes rapid evolution in an immunocompromised, chronically infected cancer patient, overcoming neutralization by two monoclonal antibody cocktail treatments Receptor binding domain (RBD) mutations emerging after monoclonal antibody treatment enable effective escape from neutralization in the absence of adaptive immunity Some emerging mutations are predicted to disrupt immunomodulatory viral proteins, including prevention of ORF8 homodimerization, mis-localization of ORF3a in host cells and alteration of the host-suppressive function of NSP1

14 September 2022 in Vox Sanguinis
Verified
Journal Article
Closed access
OGOdit Gutwein
Odit Gutwein
KTKatrin Herzog Tzarfati
Katrin Herzog Tzarfati
AAArie Apel
Arie Apel
NRNaomi Rahimi-Levene
Naomi Rahimi-Levene
HMHani Michaeli
Hani Michaeli
MKMaya Koren‐Michowitz
Maya Koren‐Michowitz